WO2007012651A1 - Pantoprazole substitue d'un point de vue isotopique - Google Patents
Pantoprazole substitue d'un point de vue isotopique Download PDFInfo
- Publication number
- WO2007012651A1 WO2007012651A1 PCT/EP2006/064669 EP2006064669W WO2007012651A1 WO 2007012651 A1 WO2007012651 A1 WO 2007012651A1 EP 2006064669 W EP2006064669 W EP 2006064669W WO 2007012651 A1 WO2007012651 A1 WO 2007012651A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- difluoromethoxy
- methoxy
- compounds
- trideuteriomethoxy
- Prior art date
Links
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical class COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 title description 15
- 229960005019 pantoprazole Drugs 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 212
- 239000003814 drug Substances 0.000 claims abstract description 13
- 150000003839 salts Chemical group 0.000 claims description 84
- 239000012453 solvate Chemical group 0.000 claims description 61
- -1 trideuteriomethoxy Chemical group 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 22
- 150000004677 hydrates Chemical class 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 17
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 13
- 229910052805 deuterium Inorganic materials 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 125000004431 deuterium atom Chemical group 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical group 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000001590 oxidative effect Effects 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 54
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 239000007787 solid Substances 0.000 description 43
- 239000000243 solution Substances 0.000 description 35
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000000203 mixture Substances 0.000 description 25
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 230000015572 biosynthetic process Effects 0.000 description 20
- 238000003756 stirring Methods 0.000 description 19
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 17
- 239000000725 suspension Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- 238000001035 drying Methods 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- UKILEIRWOYBGEJ-FIBGUPNXSA-N 6-(difluoromethoxy)-2-[[3-methoxy-4-(trideuteriomethoxy)pyridin-2-yl]methylsulfanyl]-1h-benzimidazole Chemical compound [2H]C([2H])([2H])OC1=CC=NC(CSC=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC UKILEIRWOYBGEJ-FIBGUPNXSA-N 0.000 description 10
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 159000000003 magnesium salts Chemical class 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000011734 sodium Substances 0.000 description 8
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 7
- 150000001975 deuterium Chemical group 0.000 description 7
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 230000009858 acid secretion Effects 0.000 description 6
- 239000013590 bulk material Substances 0.000 description 6
- 238000004296 chiral HPLC Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- IQPSEEYGBUAQFF-NZIJTQCXSA-N 6-(difluoromethoxy)-2-[(s)-[3-methoxy-4-(trideuteriomethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound [2H]C([2H])([2H])OC1=CC=NC(C[S@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-NZIJTQCXSA-N 0.000 description 5
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- 206010013710 Drug interaction Diseases 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000004211 gastric acid Anatomy 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 229940091250 magnesium supplement Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- BELFYULMHTWOBA-UHFFFAOYSA-N 2-[(4-chloro-3-methoxypyridin-2-yl)methylsulfanyl]-6-(difluoromethoxy)-1h-benzimidazole;hydrate Chemical compound O.COC1=C(Cl)C=CN=C1CSC1=NC2=CC(OC(F)F)=CC=C2N1 BELFYULMHTWOBA-UHFFFAOYSA-N 0.000 description 4
- RYGXNMUVOHCPBF-BMSJAHLVSA-N 4-chloro-2-methyl-3-(trideuteriomethoxy)pyridine Chemical compound [2H]C([2H])([2H])OC1=C(C)N=CC=C1Cl RYGXNMUVOHCPBF-BMSJAHLVSA-N 0.000 description 4
- IQPSEEYGBUAQFF-BFLAAXAOSA-N 6-(difluoromethoxy)-2-[(r)-[3-methoxy-4-(trideuteriomethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound [2H]C([2H])([2H])OC1=CC=NC(C[S@@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-BFLAAXAOSA-N 0.000 description 4
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000003462 sulfoxides Chemical class 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- YYRIKJFWBIEEDH-TXHXQZCNSA-N 2-(chloromethyl)-3,4-bis(trideuteriomethoxy)pyridin-1-ium;chloride Chemical compound [Cl-].[2H]C([2H])([2H])OC1=CC=[NH+]C(CCl)=C1OC([2H])([2H])[2H] YYRIKJFWBIEEDH-TXHXQZCNSA-N 0.000 description 3
- YYRIKJFWBIEEDH-NIIDSAIPSA-N 2-(chloromethyl)-3-methoxy-4-(trideuteriomethoxy)pyridin-1-ium;chloride Chemical compound [Cl-].[2H]C([2H])([2H])OC1=CC=[NH+]C(CCl)=C1OC YYRIKJFWBIEEDH-NIIDSAIPSA-N 0.000 description 3
- UKILEIRWOYBGEJ-MICDWDOJSA-N 2-[[4-(deuteriomethoxy)-3-methoxypyridin-2-yl]methylsulfanyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]COC1=CC=NC(CSC=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC UKILEIRWOYBGEJ-MICDWDOJSA-N 0.000 description 3
- IQPSEEYGBUAQFF-MICDWDOJSA-N 2-[[4-(deuteriomethoxy)-3-methoxypyridin-2-yl]methylsulfinyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]COC1=CC=NC(CS(=O)C=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC IQPSEEYGBUAQFF-MICDWDOJSA-N 0.000 description 3
- UKILEIRWOYBGEJ-DICFDUPASA-N 2-[[4-(dideuteriomethoxy)-3-methoxypyridin-2-yl]methylsulfanyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]C([2H])OC1=CC=NC(CSC=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC UKILEIRWOYBGEJ-DICFDUPASA-N 0.000 description 3
- YWYOLOVNOGZWLY-NIIDSAIPSA-N 4-chloro-2-(chloromethyl)-3-(trideuteriomethoxy)pyridin-1-ium;chloride Chemical compound [Cl-].[2H]C([2H])([2H])OC1=C(Cl)C=C[NH+]=C1CCl YWYOLOVNOGZWLY-NIIDSAIPSA-N 0.000 description 3
- YWYOLOVNOGZWLY-UHFFFAOYSA-N 4-chloro-2-(chloromethyl)-3-methoxypyridine;hydrochloride Chemical compound [Cl-].COC1=C(Cl)C=C[NH+]=C1CCl YWYOLOVNOGZWLY-UHFFFAOYSA-N 0.000 description 3
- HJMVPNAZPFZXCP-UHFFFAOYSA-N 5-(difluoromethoxy)-1,3-dihydrobenzimidazole-2-thione Chemical compound FC(F)OC1=CC=C2NC(=S)NC2=C1 HJMVPNAZPFZXCP-UHFFFAOYSA-N 0.000 description 3
- IQPSEEYGBUAQFF-SANMLTNESA-N 6-(difluoromethoxy)-2-[(s)-(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound COC1=CC=NC(C[S@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-SANMLTNESA-N 0.000 description 3
- IQPSEEYGBUAQFF-FIBGUPNXSA-N 6-(difluoromethoxy)-2-[[3-methoxy-4-(trideuteriomethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound [2H]C([2H])([2H])OC1=CC=NC(CS(=O)C=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC IQPSEEYGBUAQFF-FIBGUPNXSA-N 0.000 description 3
- UKILEIRWOYBGEJ-BMSJAHLVSA-N 6-(difluoromethoxy)-2-[[4-methoxy-3-(trideuteriomethoxy)pyridin-2-yl]methylsulfanyl]-1h-benzimidazole Chemical compound [2H]C([2H])([2H])OC1=C(OC)C=CN=C1CSC1=NC2=CC=C(OC(F)F)C=C2N1 UKILEIRWOYBGEJ-BMSJAHLVSA-N 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 3
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000003109 Karl Fischer titration Methods 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229960002626 clarithromycin Drugs 0.000 description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 150000004684 trihydrates Chemical group 0.000 description 3
- SEHIARBDRGKABK-UHFFFAOYSA-N 2-[(4-chloro-3-methoxypyridin-2-yl)methylsulfanyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound COC1=C(Cl)C=CN=C1CSC1=NC2=CC(OC(F)F)=CC=C2N1 SEHIARBDRGKABK-UHFFFAOYSA-N 0.000 description 2
- IQPSEEYGBUAQFF-DICFDUPASA-N 2-[[4-(dideuteriomethoxy)-3-methoxypyridin-2-yl]methylsulfinyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]C([2H])OC1=CC=NC(CS(=O)C=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC IQPSEEYGBUAQFF-DICFDUPASA-N 0.000 description 2
- GACDQMDRPRGCTN-KQYNXXCUSA-N 3'-phospho-5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](OP(O)(O)=O)[C@H]1O GACDQMDRPRGCTN-KQYNXXCUSA-N 0.000 description 2
- FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 description 2
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 2
- UMVFRRJTPKYVAY-BMSJAHLVSA-N 3-methoxy-2-methyl-1-oxido-4-(trideuteriomethoxy)pyridin-1-ium Chemical compound [2H]C([2H])([2H])OC1=CC=[N+]([O-])C(C)=C1OC UMVFRRJTPKYVAY-BMSJAHLVSA-N 0.000 description 2
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 0 Cc1c(CS(c2nc3cc(*)ccc3[n]2)=O)nccc1* Chemical compound Cc1c(CS(c2nc3cc(*)ccc3[n]2)=O)nccc1* 0.000 description 2
- 108010000561 Cytochrome P-450 CYP2C8 Proteins 0.000 description 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 2
- 102100029359 Cytochrome P450 2C8 Human genes 0.000 description 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 2
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 2
- 102100039208 Cytochrome P450 3A5 Human genes 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- ICTAEALXCWFQPP-KTEAADGWSA-N O.O.O.[Na].FC(OC1=CC2=C(NC(=N2)[S@](=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F Chemical compound O.O.O.[Na].FC(OC1=CC2=C(NC(=N2)[S@](=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F ICTAEALXCWFQPP-KTEAADGWSA-N 0.000 description 2
- BELFYULMHTWOBA-NIIDSAIPSA-N O.[2H]C([2H])([2H])Oc1c(Cl)ccnc1CSc1nc2cc(OC(F)F)ccc2[nH]1 Chemical compound O.[2H]C([2H])([2H])Oc1c(Cl)ccnc1CSc1nc2cc(OC(F)F)ccc2[nH]1 BELFYULMHTWOBA-NIIDSAIPSA-N 0.000 description 2
- RJRBTVMZZGMTQI-ADBWCSELSA-N O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC([2H])([2H])[2H])OC([2H])([2H])[2H])C=C1)F Chemical compound O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC([2H])([2H])[2H])OC([2H])([2H])[2H])C=C1)F RJRBTVMZZGMTQI-ADBWCSELSA-N 0.000 description 2
- 101150053185 P450 gene Proteins 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000004133 Sodium thiosulphate Substances 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229960004821 amikacin Drugs 0.000 description 2
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- OKKJLVBELUTLKV-MICDWDOJSA-N deuteriomethanol Chemical compound [2H]CO OKKJLVBELUTLKV-MICDWDOJSA-N 0.000 description 2
- OKKJLVBELUTLKV-DICFDUPASA-N dideuteriomethanol Chemical compound [2H]C([2H])O OKKJLVBELUTLKV-DICFDUPASA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 210000001853 liver microsome Anatomy 0.000 description 2
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- XPGAWFIWCWKDDL-UHFFFAOYSA-N propan-1-olate;zirconium(4+) Chemical compound [Zr+4].CCC[O-].CCC[O-].CCC[O-].CCC[O-] XPGAWFIWCWKDDL-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-NIIDSAIPSA-N sodium;trideuteriomethanolate Chemical compound [Na+].[2H]C([2H])([2H])[O-] WQDUMFSSJAZKTM-NIIDSAIPSA-N 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- ISRRJUHDGVMYLE-UHFFFAOYSA-N (4-chloro-3-methoxypyridin-2-yl)methanol Chemical compound COC1=C(Cl)C=CN=C1CO ISRRJUHDGVMYLE-UHFFFAOYSA-N 0.000 description 1
- PWWDEIMGEBPTJL-UHFFFAOYSA-N 1-(pyridin-2-ylmethylsulfinyl)benzimidazole Chemical class C1=NC2=CC=CC=C2N1S(=O)CC1=CC=CC=N1 PWWDEIMGEBPTJL-UHFFFAOYSA-N 0.000 description 1
- OXXDGKNPRNPMLS-UHFFFAOYSA-N 2-Hydroxy-3-methyl-4H-pyran-4-one Natural products CC1=C(O)OC=CC1=O OXXDGKNPRNPMLS-UHFFFAOYSA-N 0.000 description 1
- IQPSEEYGBUAQFF-JFGMNRAASA-N 2-[(r)-[4-(dideuteriomethoxy)-3-methoxypyridin-2-yl]methylsulfinyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]C([2H])OC1=CC=NC(C[S@@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-JFGMNRAASA-N 0.000 description 1
- IQPSEEYGBUAQFF-SFRSKVPJSA-N 2-[(s)-[4-(dideuteriomethoxy)-3-methoxypyridin-2-yl]methylsulfinyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]C([2H])OC1=CC=NC(C[S@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-SFRSKVPJSA-N 0.000 description 1
- RYOOHIUJEJZCFT-UHFFFAOYSA-N 2-[2-(diethylamino)ethylamino]-2-phenylacetic acid 3-methylbutyl ester Chemical compound CCN(CC)CCNC(C(=O)OCCC(C)C)C1=CC=CC=C1 RYOOHIUJEJZCFT-UHFFFAOYSA-N 0.000 description 1
- XILVEPYQJIOVNB-UHFFFAOYSA-N 2-[3-(trifluoromethyl)anilino]benzoic acid 2-(2-hydroxyethoxy)ethyl ester Chemical compound OCCOCCOC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 XILVEPYQJIOVNB-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- IQPSEEYGBUAQFF-QDNHWIQGSA-N 2-[[3,4-bis(deuteriomethoxy)pyridin-2-yl]methylsulfinyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]COC1=CC=NC(CS(=O)C=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC[2H] IQPSEEYGBUAQFF-QDNHWIQGSA-N 0.000 description 1
- IQPSEEYGBUAQFF-LNLMKGTHSA-N 2-[[3,4-bis(dideuteriomethoxy)pyridin-2-yl]methylsulfinyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]C([2H])OC1=CC=NC(CS(=O)C=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC([2H])[2H] IQPSEEYGBUAQFF-LNLMKGTHSA-N 0.000 description 1
- UKILEIRWOYBGEJ-WFGJKAKNSA-N 2-[[3,4-bis(trideuteriomethoxy)pyridin-2-yl]methylsulfanyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]C([2H])([2H])OC1=CC=NC(CSC=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC([2H])([2H])[2H] UKILEIRWOYBGEJ-WFGJKAKNSA-N 0.000 description 1
- IQPSEEYGBUAQFF-WFGJKAKNSA-N 2-[[3,4-bis(trideuteriomethoxy)pyridin-2-yl]methylsulfinyl]-6-(difluoromethoxy)-1h-benzimidazole Chemical compound [2H]C([2H])([2H])OC1=CC=NC(CS(=O)C=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC([2H])([2H])[2H] IQPSEEYGBUAQFF-WFGJKAKNSA-N 0.000 description 1
- VPGBIRMKRPLRKJ-XERRXZQWSA-N 2-methyl-3,4-bis(trideuteriomethoxy)pyridine Chemical compound CC1=NC=CC(=C1OC([2H])([2H])[2H])OC([2H])([2H])[2H] VPGBIRMKRPLRKJ-XERRXZQWSA-N 0.000 description 1
- GNWSQENQZGWCSW-BMSJAHLVSA-N 2-methyl-3-(trideuteriomethoxy)-1h-pyridin-4-one Chemical compound [2H]C([2H])([2H])OC1=C(C)NC=CC1=O GNWSQENQZGWCSW-BMSJAHLVSA-N 0.000 description 1
- NGGPLHHTRNJSDT-BMSJAHLVSA-N 2-methyl-3-(trideuteriomethoxy)pyran-4-one Chemical compound [2H]C([2H])([2H])OC1=C(C)OC=CC1=O NGGPLHHTRNJSDT-BMSJAHLVSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- GMZALNFVKYJBJJ-FIBGUPNXSA-N 3-methoxy-4-(trideuteriomethoxy)-1h-pyridin-2-one Chemical compound [2H]C([2H])([2H])OC=1C=CNC(=O)C=1OC GMZALNFVKYJBJJ-FIBGUPNXSA-N 0.000 description 1
- TWXMQDRFBLSXFN-UHFFFAOYSA-N 4-chloro-3-methoxy-2-methyl-1-oxidopyridin-1-ium Chemical compound COC1=C(C)[N+]([O-])=CC=C1Cl TWXMQDRFBLSXFN-UHFFFAOYSA-N 0.000 description 1
- RYGXNMUVOHCPBF-UHFFFAOYSA-N 4-chloro-3-methoxy-2-methylpyridine Chemical compound COC1=C(C)N=CC=C1Cl RYGXNMUVOHCPBF-UHFFFAOYSA-N 0.000 description 1
- IQPSEEYGBUAQFF-AREMUKBSSA-N 6-(difluoromethoxy)-2-[(r)-(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical compound COC1=CC=NC(C[S@@](=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-AREMUKBSSA-N 0.000 description 1
- WHCXDEORRDVLKS-FOWCFNCZSA-N 6-(difluoromethoxy)-2-[(r)-[3-methoxy-4-(trideuteriomethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole;sodium Chemical compound [Na].[2H]C([2H])([2H])OC1=CC=NC(C[S@@](=O)C=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC WHCXDEORRDVLKS-FOWCFNCZSA-N 0.000 description 1
- IQPSEEYGBUAQFF-BMSJAHLVSA-N 6-(difluoromethoxy)-2-[[4-methoxy-3-(trideuteriomethoxy)pyridin-2-yl]methylsulfinyl]-1h-benzimidazole Chemical compound [2H]C([2H])([2H])OC1=C(OC)C=CN=C1CS(=O)C1=NC2=CC=C(OC(F)F)C=C2N1 IQPSEEYGBUAQFF-BMSJAHLVSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101100497948 Caenorhabditis elegans cyn-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 244000258136 Costus speciosus Species 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- MADWPVWUCONOAD-CKTWJNPWSA-N O.O.O.[Mg].FC(OC1=CC2=C(NC(=N2)[S@](=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F.FC(OC1=CC2=C(NC(=N2)[S@](=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F Chemical compound O.O.O.[Mg].FC(OC1=CC2=C(NC(=N2)[S@](=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F.FC(OC1=CC2=C(NC(=N2)[S@](=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F MADWPVWUCONOAD-CKTWJNPWSA-N 0.000 description 1
- XSCJMXARYJIGEY-ZXDIQWFJSA-N O.[Mg++].[2H]C([2H])([2H])Oc1ccnc(CS(=O)C2Nc3ccc(OC(F)F)cc3[N-]2)c1OC.[2H]C([2H])([2H])Oc1ccnc(CS(=O)[C@@H]2Nc3ccc(OC(F)F)cc3[N-]2)c1OC Chemical compound O.[Mg++].[2H]C([2H])([2H])Oc1ccnc(CS(=O)C2Nc3ccc(OC(F)F)cc3[N-]2)c1OC.[2H]C([2H])([2H])Oc1ccnc(CS(=O)[C@@H]2Nc3ccc(OC(F)F)cc3[N-]2)c1OC XSCJMXARYJIGEY-ZXDIQWFJSA-N 0.000 description 1
- GOFZMQCVGPJUAH-XNUKZBLJSA-N O.[Na+].[2H]C([2H])([2H])Oc1ccnc(CS(=O)[C@@H]2Nc3ccc(OC(F)F)cc3[N-]2)c1OC Chemical compound O.[Na+].[2H]C([2H])([2H])Oc1ccnc(CS(=O)[C@@H]2Nc3ccc(OC(F)F)cc3[N-]2)c1OC GOFZMQCVGPJUAH-XNUKZBLJSA-N 0.000 description 1
- RJRBTVMZZGMTQI-GXXYEPOPSA-N O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F Chemical compound O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F RJRBTVMZZGMTQI-GXXYEPOPSA-N 0.000 description 1
- ZEPXBFIPCFSUOZ-BMYPLOHWSA-N O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F.O.O.FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F.[Na] Chemical compound O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F.O.O.FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC([2H])([2H])[2H])C=C1)F.[Na] ZEPXBFIPCFSUOZ-BMYPLOHWSA-N 0.000 description 1
- RJRBTVMZZGMTQI-SRTIKVJZSA-N O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC([2H])[2H])C=C1)F Chemical compound O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC([2H])[2H])C=C1)F RJRBTVMZZGMTQI-SRTIKVJZSA-N 0.000 description 1
- RJRBTVMZZGMTQI-QCNSCHFVSA-N O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC[2H])C=C1)F Chemical compound O.[Na].FC(OC1=CC2=C(NC(=N2)S(=O)CC2=NC=CC(=C2OC)OC[2H])C=C1)F RJRBTVMZZGMTQI-QCNSCHFVSA-N 0.000 description 1
- DUDKAZCAISNGQN-UHFFFAOYSA-N Oxyphencyclimine Chemical compound CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 DUDKAZCAISNGQN-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- BKTHTLOKUUJKDF-WFGJKAKNSA-N [3,4-bis(trideuteriomethoxy)pyridin-2-yl]methanol Chemical compound [2H]C([2H])([2H])OC1=CC=NC(CO)=C1OC([2H])([2H])[2H] BKTHTLOKUUJKDF-WFGJKAKNSA-N 0.000 description 1
- BKTHTLOKUUJKDF-FIBGUPNXSA-N [3-methoxy-4-(trideuteriomethoxy)pyridin-2-yl]methanol Chemical compound [2H]C([2H])([2H])OC1=CC=NC(CO)=C1OC BKTHTLOKUUJKDF-FIBGUPNXSA-N 0.000 description 1
- ISRRJUHDGVMYLE-FIBGUPNXSA-N [4-chloro-3-(trideuteriomethoxy)pyridin-2-yl]methanol Chemical compound [2H]C([2H])([2H])OC1=C(Cl)C=CN=C1CO ISRRJUHDGVMYLE-FIBGUPNXSA-N 0.000 description 1
- CHIKXBBAVDNRFS-XQUJKGEFSA-N [Na+].[2H]C([2H])([2H])Oc1ccnc(CS(=O)[C@@H]2Nc3ccc(OC(F)F)cc3[N-]2)c1OC Chemical compound [Na+].[2H]C([2H])([2H])Oc1ccnc(CS(=O)[C@@H]2Nc3ccc(OC(F)F)cc3[N-]2)c1OC CHIKXBBAVDNRFS-XQUJKGEFSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005227 alkyl sulfonate group Chemical group 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 230000000026 anti-ulcerogenic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- JGTJANXYSNVLMQ-UHFFFAOYSA-N bietamiverine Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(CC)CC)N1CCCCC1 JGTJANXYSNVLMQ-UHFFFAOYSA-N 0.000 description 1
- 229950005940 bietamiverine Drugs 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960005242 camylofin Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 229960001493 etofenamate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960003174 lansoprazole Drugs 0.000 description 1
- SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229960004018 magaldrate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- CRGZYKWWYNQGEC-UHFFFAOYSA-N magnesium;methanolate Chemical compound [Mg+2].[O-]C.[O-]C CRGZYKWWYNQGEC-UHFFFAOYSA-N 0.000 description 1
- YYINWHOQKIUBNL-UHFFFAOYSA-N magnesium;trihydrate Chemical compound O.O.O.[Mg] YYINWHOQKIUBNL-UHFFFAOYSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 229960002369 oxyphencyclimine Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- SPPNVMTVMQOKSC-UHFFFAOYSA-A pentaaluminum decamagnesium hentriacontahydroxide disulfate hydrate Chemical compound O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O SPPNVMTVMQOKSC-UHFFFAOYSA-A 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960005335 propanol Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- BZGIPVGCJGXQTA-UHFFFAOYSA-N s-[2-(diethylamino)ethyl] n,n-diphenylcarbamothioate Chemical compound C=1C=CC=CC=1N(C(=O)SCCN(CC)CC)C1=CC=CC=C1 BZGIPVGCJGXQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 229950008375 tenatoprazole Drugs 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
Definitions
- the present invention relates to isotopically substituted pantoprazole and its (R)- and (S)-enantiomers. These compounds can be used in the pharmaceutical industry for preparing pharmaceutical compositions.
- pyridin-2-ylmethylsulphinyl-1 H-benzimidazoles such as those known, for example, from EP-A-0005129, EP-A-0166287, EP-A-0174726, EP-A-0254588 and EP-A-0268956 are of considerable importance in the therapy of disorders associated with an increased secretion of gastric acid.
- Examples of active compounds from this group which are commercially available or in clinical development are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole (INN: omeprazole), (S)-5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole (INN: esomeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulphinyl]-1 H-benzimidazole (INN: lansoprazole), 2- ⁇ [4-(3-methoxypropoxy)-3-methylpyridin
- PPI proton pump inhibitors
- US Patent 6,818,200 discloses dihydropyridine compounds and antibiotics wherein at least one hydrogen atom is replaced by a deuterium atom.
- the deuterated compounds are obtained by reacting the H- form with mixtures of deuterium oxide and a suitable catalyst in sealed vessels at drastic reaction conditions, i.e. at elevated temperatures (60-80 0 C) and for prolonged reaction times (up to 190 hours). It further discloses some influence on the pharmacological properties of these compounds due to the H/D exchange.
- the invention relates to compounds of the general formula 1
- R1 is difluormethoxy
- R2 is methoxy
- R3 is methoxy and salts, solvates, preferably hydrates and solvates of the salts, preferably hydrates of the salts thereof, wherein at least one of the hydrogen atoms of R1 , R2, R3 or any combination of R1 , R2 and R3 is replaced by a deuterium atom.
- Possible combinations are R1 and R2, R1 and R3, R2 and R3 or R1 and R2 and R3.
- salts with inorganic and organic bases are included, in particular the salts with alkali metals, such as the lithium, sodium and potassium salts, or the salts with alkaline earth metals, such as the magnesium and calcium salts, but also other pharmacologically compatible salts, such as, for example, the aluminium or the zinc salts.
- alkali metals such as the lithium, sodium and potassium salts
- alkaline earth metals such as the magnesium and calcium salts
- other pharmacologically compatible salts such as, for example, the aluminium or the zinc salts.
- the sodium and the magnesium salts are particularly preferred.
- Pharmacologically incompatible salts which can initially be obtained, for example, as process products in the production of the compounds according to the invention on the industrial scale, which are also within the scope of the invention, are - for the production of medicaments - converted into the pharmacologically tolerable salts by processes known to the person skilled in the art.
- the compounds according to the invention and their salts if, for example, they are isolated in crystalline form, can contain various amounts of solvents.
- the invention therefore also comprises all solvates and in particular all hydrates of the compounds of the formula 1 , and also all solvates and in particular all hydrates of the salts of the compounds of the formula 1.
- solvates all pharmaceutically acceptable solvents resulting in such solvates are included.
- the term "at least one" refers to 1 to 3 hydrogen atoms of R2 or R3, which can be replaced by deuterium atoms. - -
- deutero or “deuterio” should indicate a deuterium atom ([ 2 H]).
- tri or “tris” should indicate the occurrence of three, for example deuterio atoms in a specific group, i.e. trideuteriomethoxy.
- R1 is deuteriodifluoromethoxy.
- examples of such compounds may be 5-difluoromethoxy-2-[(3-methoxy-4- monodeuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1 H-benzimidazole, 5-difluoromethoxy-2-[(3-methoxy- 4-dideuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1 H-benzimidazole, 5-difluoromethoxy-2-[3- monodeuteriomethoxy-4-methoxy)-2-pyridinyl)methylsulfinyl]-1 H-benzimidazole, 5-difluoromethoxy-2- [(3-dideuteriomethoxy-4-methoxy)-2-pyridinyl)methylsulfinyl]-1 H-benzimidazole, 5-difluoromethoxy-2- [(3-dideuteriomethoxy-4-meth
- R2, R3 or R2 and R3 is trideuteriomethoxy. More preferred is a compound wherein R3 is trideuteriomethoxy.
- examples of such compounds may be 5- difluoromethoxy-2-[(3-trideuteriomethoxy-4-methoxy-2-pyridinyl)methylsulfinyl]-1 H-benzimidazole, 5- difluoromethoxy-2-[(3-methoxy-4-trideuteriomethoxy-2-pyridinyl)methylsulfinyl]-1 H-benzimidazole or 5- difluoromethoxy-2-[(3,4-bis(trideuteriomethoxy)-2-pyridinyl)methylsulfinyl]-1 H-benzimidazole.
- R1 is difluoromethoxy
- R2 is methoxy
- R3 is dideute- riomethoxy or trideuteriomethoxy.
- the sodium or magnesium salt of a compound of formula 1 is a monohydrate salt and, even more preferred, a sesquihydrate salt.
- the magnesium salt is a trihydrate salt and, even more preferred, a dihydrate salt.
- the compounds according to the invention show significant improved properties with respect to the known compounds concerning the influences on secretion of gastric acid.
- the compounds according to the invention are chiral compounds.
- the invention thus relates to the racemates as well as to the enantiomers and mixtures thereof in any desired ratio.
- a preferred subject matter of the inventions are the enantiomers of the compounds of formula 1 , preferably the enantiomers being substantially free of the respective other enantiomer with opposite configuration.
- R1, R2 and R3 have the meanings given above.
- a particularly preferred compound with (S)-configuration within the scope of the invention is the compound (S)-5-difluoromethoxy-2-[(3-methoxy-4-trideuteriomethoxy-2-pyridylmethyl)sulphinyl]-1 H- benzimidazole and the solvates, preferably hydrates of this compound, the salts of this compound and the solvates, preferably hydrates of the salts of this compound.
- Another particularly preferred compound with (S)-configuration within the scope of the invention is the compound (S)-5-difluoromethoxy- 2-[(3-methoxy-4-dideuteriomethoxy-2-pyridylmethyl)sulphinyl]-1 H-benzimidazole and the solvates, preferably hydrates of this compound, the salts of this compound and the solvates, preferably hydrates of the salts of this compound.
- the sodium or magnesium salt of a compound of formula 1 a is a trihydrate.
- R1, R2 and R3 have the meanings given above.
- a particularly preferred compound with (R)-configuration within the scope of the invention is the compound (R)-5-difluoromethoxy-2-[(3-methoxy-4-trideuteriomethoxy-2-pyridylmethyl)sulphinyl]-1 H- benzimidazole and the solvates, preferably hydrates of this compound, the salts of this compound and the solvates, preferably hydrates of the salts of this compound.
- Another particularly preferred compound with (R)-configuration within the scope of the invention is the compound (R)-5-difluoromethoxy- 2-[(3-methoxy-4-dideuteriomethoxy-2-pyridylmethyl)sulphinyl]-1 H-benzimidazole and the solvates, preferably hydrates of this compound, the salts of this compound and the solvates, preferably hydrates of the salts of this compound.
- the separation of the compounds of formula 1 into the enantiomers can be accomplished according to various processes, for example as described in international patent application WO92/08716 or by column chromatography.
- the compounds of formulae 1a and 1b can be obtained by chiral oxidation of the sulphides as described in international patent application WO 2004/052881.
- the salts of the compounds of formulae 1 , 1a and 1 b are prepared by processes known per se by reacting the compounds of formulae 1 , 1a, and 1 b, which can be regarded as weak acids, with suitable bases, for example with alkali metal hydroxides or alkoxides, such as sodium hydroxide or sodium methoxide, or with alkaline earth metal alkoxides, such as magnesium methoxide.
- suitable bases for example with alkali metal hydroxides or alkoxides, such as sodium hydroxide or sodium methoxide, or with alkaline earth metal alkoxides, such as magnesium methoxide.
- the magnesium salts of the compounds of formulae 1 , 1a and 1 b which are - besides the sodium salts - the preferred salts, are prepared in a manner known per se by reacting compounds of formulae 1 , 1a and 1 b with a magnesium base, for example a magnesium alkoxide, or from a readily soluble salt of a compound of formulae 1 , 1a and 1 b (for example of a sodium salt) using a magnesium salt in water or in mixtures of water with polar organic solvents (for example alcohols, preferably methanol, ethanol or isopropanol, or ketones, preferably acetone).
- a magnesium base for example a magnesium alkoxide
- a readily soluble salt of a compound of formulae 1 , 1a and 1 b for example of a sodium salt
- polar organic solvents for example alcohols, preferably methanol, ethanol or isopropanol, or ketones, preferably acetone.
- substantially free in the context of the invention means that the compounds with (S)-configuration and/or their salts, solvates or solvates of salts contain less than 10 % by weight of compounds with (R)-configuration and/or their salts, solvates or solvates of salts.
- substantially free means that compounds with (S)-configuration and/or their salts, solvates or solvates of salts contain less than 5 % by weight of compounds with (R)-configuration and/or their salts, solvates or solvates of salts.
- substantially free means that compounds with (S)-configuration and/or their salts, solvates or solvates of salts contain less than 2 % by weight of compounds with (R)-configuration and/or their salts, solvates or solvates of salts. In the most preferred embodiment, “substantially free” means that compounds with (S)-configuration and/or their salts, solvates or solvates of salts contain less than 1 % by weight of compounds with (R)-configuration and/or their salts, solvates or solvates of salts.
- substantially free in the context of the invention means that the compounds with (R)-configuration and/or their salts, solvates or solvates of salts contain less than 10 % by weight of compounds with (S)-configuration and/or their salts, solvates or solvates of salts.
- substantially free means that compounds with (R)-configuration and/or their salts, solvates or solvates of salts contain less than 5 % by weight of compounds with (S)-configuration and/or their salts, solvates or solvates of salts.
- substantially free means that compounds with (R)-configuration and/or their salts, solvates or solvates of salts contain less than 2 % by weight of compounds with (S)-configuration and/or their salts, solvates or solvates of salts.
- substantially free means that compounds with (R)-configuration and/or their salts, solvates or solvates of salts contain - - less than 1 % by weight of compounds with (S)-configuration and/or their salts, solvates or solvates of salts.
- the term "hydrogen atom replaced by a deuterium atom” has to be understood as defining a degree of deuteration of at least 80 % for the bulk material, where all these correspondingly mentioned hydrogen atoms are replaced by deuterium atoms.
- the substitu- ent R2 or R3 refers to a methoxy group having all three "hydrogen atoms replaced by a deuterium atoms” it is to be understood according to the above definition that at least 80% of all the R2 or R3 methoxy groups in the bulk material are -OCD 3 .
- the remaining part up to 100% includes -OCHD 2 , - OCH 2 D Or-OCH 3 .
- R1 , R2 and R3 have the meanings as given above and wherein at least one of the hydrogen atoms of R1 , R2, R3 or any combination of R1 , R2 and R3 is replaced by a deuterium atom.
- Possible combinations are R1 and R2, R1 and R3, R2 and R3 or R1 and R2 and R3.
- the compounds of formula 2 include further their salts with acid, preferably the hydrochloride, the sulphate or the phosphate salts, and/or solvates. These compounds can be used for the manufacture of compounds of general formula 1, 1a or 1b.
- the compounds of formula 2 are suitable especially as starting material for an oxidation reaction resulting in compounds according formulae 1 , 1 a or 1 b.
- Another aspect of the invention are compounds of formula 3
- X is a halogen or an activated derivative of an alcohol and R2 and R3 have the meanings as given above and wherein at least one of the hydrogen atoms of R2, R3 or R2 and R3 is replaced by a deuterium atom.
- halogen is iodine, bromine, chlorine and fluorine.
- X is chlorine.
- an activated derivate of an alcohol is an alkylsulfonate group, for example mesylate or an arylsulfonate group, for example tosylate or besylate, or a perfluoroalkanesul- fonate group, for example trifluoromethanesulfonate.
- the compounds of formula 3 can be used for the manufacture of compounds of formula 1 , 1 a or 1 b.
- the nitrogen atom of compound of formula 3 is first quatemised and then reacted with compounds of formula 4
- R1 has the meaning as given above, thus providing compounds of formula 2 as described above.
- the deuterium homologes of R/S pantoprazole and S-pantoprazole can be prepared by oxidation of the corresponding thio-compounds according to methods known from literature, e.g. Kohl et al. J. Med. Chem. 1992, 35, 1049 ff. or WO 2004/052881 or by exchange of halogen for trideuteriomethoxy from the corresponding sulfoxides with a halogen (e.g. chloro, bromo or nitro) substituent at the position of the final trideuteriomethoxy group, in particular in 4-position of the pyridine group.
- a halogen e.g. chloro, bromo or nitro
- the thiocompounds are prepared either by exchange of halogen by trideuteriomethoxy at the position of the final trideuteriomethoxy-substituent or by coupling of 5-difluoromethoxy-2- mercaptobenzimidazole with the accordingly substituted 2-chloromethyl-3-methoxy-4- trideuteriomethoxy-pyridinumchloride.
- the disclosed preparation routes can also be used to substitute the halogen by dideuteriomethoxy or monodeuteriomethoxy instead of trideuteriomethoxy as described above. These syntheses will lead to the correspondingly deuterated compounds.
- the compound of formula 1 can be prepared according to the following reaction scheme: - -
- Salts of the sulfoxides with anorganic bases are prepared according to methods known from literature by reaction of the sulfoxides with the corresponding hydroxides or alkoxides in organic solvents or mixtures of organic solvents with water.
- salts are prepared by reaction of sulfoxides with alkali hydroxides to give the corresponding alkali salt (Na, K, Li) and further reaction with e.g. magnesium, calcium, aluminum, zinc salts.
- methanol-d4 As trideuteriomethoxylation agent, methanol-d4 with >99.8 atom% D was used. Isomeric purity of the trideuteriomethoxy substituent(s) in all resulting products was >98.0% as determined by NMR and MS. As further deuteration agents, methanol-d2 with >98.0 atom% D, and methanol-d1 with >98.0 atom% D were used. Isomeric purity of the dideuteriomethoxy and monodeuteriomethoxy substituents in the resulting products was >96.0% as determined by NMR and MS.
- a solution of sodium hypochlorite (10 % strength) (3.3 mmol) is added over one to two hours to a slurry of 5-difluoromethoxy-2-[(3-methoxy-4-trideuteriomethoxy-2-pyridinyl) methylthio]-1 H-benzimidazole (1.0 g, 2.7 mmol) in water (20 ml_), 2-propanol (10 ml.) and sodium hydroxide (0.5 ml.40 % strength solution, 7.1 mmol) at 30-35 0 C with stirring. After 30-60 minutes at the stated temperature sodium thiosulfate (0.3 g dissolved in 5 ml. of water) is added and stirring is continued for a further 15-30 minutes.
- reaction mixture is concentrated in vacuo (30-40 0 C) to about one third of the original volume and water (about 70 mL) is added.
- N-ethyldiisopropylamine (0.07 mL) and cumene hydroperoxide (1.05 mL) are added.
- the mixture is stirred at room temperature until the oxidation has ended (10-24 hours, monitored by TLC).
- the clear solution is diluted with 10 mL of methyl isobutyl ketone and quenched with 0.08 g of sodium thiosulphate in 14 mL of saturated sodium bicarbonate solution and stirred for a further 2 hours. After phase separation the mixture is washed twice with 5 mL of saturated sodium bicarbonate solution.
- reaction mixture After four hours at the stated temperature the reaction mixture is cooled to 20 - 25 0 C and water (500 ml.) is added over 1 - 2 hours while stirring. After adjustment to pH 7 with 2N aqueous hydrochloric acid the mixture is stirred for a further hour at 20-25 0 C.
- the precipitate is filtered off over a suction filter, rinsed with water (200 mL) in several portions and dried (35 0 C, 20 mbar, 20 hours).
- the dried crude product (22 g) is dissolved in toluene (250 mL) at 80-85 0 C and aluminium oxide (Merck, 90 active basic; 10 g) is added. After stirring for 30 minutes at the stated temperature the mixture is filtered and the clear filtrate is concentrated in vacuo (40-50 0 C) to a volume of 50 mL.
- the resulting suspension is stirred at an internal temperature of ⁇ 20 0 C for 18 h.
- the suspension is then filtered, and the crystals are washed with 5 ml of acetone. Drying is carried out in a vacuum drying cabinet at ⁇ 50 mbar and 40 0 C.
- the title compound is achieved as white to off white crystalline solid; yield 8.8 g, 88 % of theory;
- the water content is 5,2 %, by Karl Fischer titration, corresponding to a monohydrate; m.p.: 155 - 158°C (decomposition), purity > 99.3 % by HPLC.
- reaction mixture was cooled to 20-30 0 C and diluted with water (21 L) before the pH was adjusted to 7-8 with 20% aqueous HCI ( ⁇ 7.5 L). Precipitation of product was achieved by addition of water (75 h) over about 4 h. The resulting slurry was heated to 35-45 0 C for 1.5 h before being chilled to 10-15 0 C.
- the resulting slightly turbid aqueous solution was washed twice with MIBK (12 L each) and cleared by Hyflo treatment (0.40 kg), before the pH was adjusted to 9.0-9.5 by addition of 10% aqueous acetic acid (-8 L) at 40-45 0 C. Once product started to crystallize, further 10% acetic acid was added so as to continuously maintain a pH of 9.0-9.5.
- the organic layer was extracted with another 400 mL of water at pH 13. After treatment with Hyflo Super CeI (5.0 g), the pH of the combined aqueous phase is adjusted to about 9 by addition of 10% aqueous acetic acid at 40 - 45 0 C. Once precipitation of product had set in, the mixture was stirred for another 12 h with eventual readjustment of the pH. Crude product (160 g, 75% yield) with an optical purity of > 98 % was obtained by filtration including an aqueous rinse (200 mL).
- the compounds of the general formula 1 and their salts and solvates, preferably hydrates, and the solvates, preferably hydrates of the salts have useful pharmacological properties, rendering them commercially utilizable. In particular, they have a pronounced inhibitory effect on the secretion of gastric acid and excellent gastrointestinal protective action in warmblooded animals, in particular man.
- the compounds according to the invention are distinguished by a highly selective action, an advantageous duration of action, a particularly high bioavailability, a metabolization profile that is uniform among different individuals, the lack of significant side-effects and a wide therapeutic spectrum.
- gastrointestinal protection is to be understood as the prevention and treatment of gastrointestinal disorders, in particular gastrointestinal inflammatory disorders and lesions (such as, for example, Ulcus ventriculi, Ulcus duodeni, gastritis, irritable bowel owing to an increased production of acid or as a result of medicaments, GERD, Crohn's disease, IBD) which may be caused, for example, by microorganisms (for example Helicobacter pylori), bacterial toxins, medicaments (for example certain antiphlogistics and antirheumatic drugs), chemicals (for example ethanol), gastric acid or stress.
- microorganisms for example Helicobacter pylori
- medicaments for example certain antiphlogistics and antirheumatic drugs
- chemicals for example ethanol
- the compounds according to the invention in various models for the determination of antiulcerogenic and antisecretory properties, surprisingly prove to be clearly superior to the prior art compounds, in particular with respect to their metabolization properties.
- These improved metabolization properties allow for example a reduction of the amount of a compound according to the invention, which is needed for treatment or prophylaxis. Or by using the same amount of the compound according to the invention as done for the prior art compounds a longer duration of action may be achieved.
- advantages concerning patient safety or economical aspects e.g. like drug costs etc..
- the compounds according to the invention are highly suitable for use in human and veterinary medicine, where they are used, in particular, for the treatment and/or prophylaxis of gastrointestinal disorders.
- the invention furthermore provides the use of the compounds of the invention for the treatment and/or prophylaxis of the abovementioned diseases.
- the invention also embraces the use of the compounds of the invention for preparing pharmaceutical compositions used for the treatment and/or prophylaxis of the abovementioned diseases.
- the invention also provides pharmaceutical compositions comprising the compounds of the invention.
- the invention provides pharmaceutical compositions containing the compounds of formulae 1 , 1 a or 1 b in the form of their pharmaceutically acceptable salts, in particular in the form of a sodium or magnesium salt, and/or in the form of a hydrate of such salt.
- compositions are prepared by processes known per se which are familiar to the person skilled in the art.
- the compounds according to the invention are employed either as such or, preferably, in combination with suitable pharmaceutical auxiliaries or carriers in the form of tablets, coated tablets, capsules, suppositories, plasters (for example as TTS), emulsions, suspensions or solutions, where the content of active compound is advantageously from about 0.1 to about 95% and where it is possible to produce pharmaceutical dosage forms (for example flow-release forms or enteric forms) which, by the appropriate choice of auxiliaries and carriers, are tailored for the active compound and/or the desired onset of action and/or the duration of action.
- suitable pharmaceutical auxiliaries or carriers in the form of tablets, coated tablets, capsules, suppositories, plasters (for example as TTS), emulsions, suspensions or solutions, where the content of active compound is advantageously from about 0.1 to about 95% and where it is possible to produce pharmaceutical dosage forms (for example flow-release forms or enteric forms) which, by the appropriate
- auxiliaries or carriers suitable for the desired pharmaceutical formulations are known to the person skilled in the art.
- solvents for example, antioxidants, dispersants, emulsifiers, antifoams, flavour-masking agents, preservatives, solubilizers, colorants or, in particular, permeation promoters and complex formers (for example cyclodextrins).
- the compounds of the invention can be administered orally, parenterally or percutaneously. Preferably, the compounds of the invention are administered orally.
- a further aspect of the invention is thus a pharmaceutical composition, comprising one or more compound according to the invention together with one or more customary auxiliaries, where the single dose comprises from about 2 to about 60 mg of the free compound.
- a further aspect of the invention is a pharmaceutical composition, comprising one or more compound according to the invention together with one or more customary auxiliaries, where the single dose comprises from about 4 to about 40 mg of the free compound.
- a further aspect of the invention is the use of the compounds according to the invention for treating gastrointestinal disorders.
- a further aspect of the invention is the use of the compounds according to the invention for the manufacture of pharmaceutical composition for the treatment or prophylaxis of gastrointestinal disorders. - -
- a further aspect of the invention is a method of treating gastrointestinal disorders by administering a pharmaceutical composition comprising one or more compounds according to the invention.
- a further aspect of the invention is the use of the compounds according to the invention for treating gastrointestinal disorders in patients who are slow metabolizers.
- a further aspect of the invention is the use of the compounds according to the invention hereof for treating gastrointestinal disorders in patients who have a risk of drug interactions.
- a further aspect of the invention is the use of the compounds according to the invention for treating gastrointestinal disorders in patients who need an inhibition of acid secretion for an extended period of time.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who are slow metabolizers, comprising one or more compound according to the invention together with one or more customary auxiliaries, where the single dose comprises from about 2 to about 60 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who are slow metabolizers, comprising one or more compound according to the invention together with one or more customary auxiliaries, where the single dose comprises from about 4 to about 40 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who have a risk of drug interactions, comprising one or more compound according to the invention together with one or more customary auxiliaries, where the single dose comprises from about 2 to about 60 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who have a risk of drug interactions, comprising one or more compound according to the invention together with one or more customary auxiliaries, where the single dose comprises from about 4 to about 40 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for an extended period of time, comprising one or more compound according to the invention together with one or more customary auxiliaries, where the single dose comprises from about 2 to about 60 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for an extended period of time, comprising one or more compound according to the invention together with one or more customary auxiliaries, where the single dose comprises from about 4 to about 40 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who are slow metabolizers, comprising in an oral solid application form a pharmaceutically acceptable salt according to the invention or a hydrate thereof together with one or more customary auxiliaries, where the single dose comprises from about 2 to about 60 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who are slow metabolizers, comprising in an oral solid application form a pharmaceutically salt according to the invention or a hydrate thereof together with one or more customary auxiliaries, where the single dose comprises from about 4 to about 40 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who have a risk for drug interactions, comprising in an oral solid application form a pharmaceutically acceptable salt according to the invention or a hydrate thereof together with one or more customary auxiliaries, where the single dose comprises from about 2 to about 60 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who have a risk for drug interactions, comprising in an oral solid application form a pharmaceutically acceptable salt according to the invention or a hydrate thereof together with one or more customary auxiliaries, where the single dose comprises from about 4 to about 40 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for an extended period of time, comprising in an oral solid application form a pharmaceutically acceptable salt according to the invention or a hydrate thereof together with one or more customary auxiliaries, where the single dose comprises from about 2 to about 60 mg of free compound.
- a further aspect of the invention is a pharmaceutical composition for treating gastrointestinal disorders for use in patients who need an inhibition of acid secretion for an extended period of time, comprising in an oral solid application form a pharmaceutically acceptable salt according to the invention or a hydrate thereof together with one or more customary auxiliaries, where the single dose comprises from about 4 to about 40 mg of free compound.
- the pharmaceutical preparations may also comprise one or more pharmacologically active ingredients from other groups of medicaments.
- pharmacologically active ingredients from other groups of medicaments.
- examples that may be mentioned include tranquilizers (for example from the group of the benzodiazepines, e. g., diazepam), spasmolytic drugs (e. g., bietamiverine or camylofine), anticholinergic drugs (e. g., oxyphencyclimine or phencarbamide), local anesthetics (e. g., tetracaine or procaine), and optionally also enzymes, vitamins or amino acids.
- tranquilizers for example from the group of the benzodiazepines, e. g., diazepam
- spasmolytic drugs e. g., bietamiverine or camylofine
- anticholinergic drugs e. g., oxyphencyclimine or phencarbamide
- NSAIDs such as, for example, etofenamate, diclofenac, indometacin, ibuprofen or piroxicam
- TLOSR transient lower esophageal sphincter relaxation
- antibacterial substances such as, for example, cephalosporins, tetracyclins, penicillins, mac- rolides, nitroimidazoles or else bismuth salt
- Antibacterial combination partners that may be mentioned include, for example, mezlocillin, ampicillin, amoxicillin, cefalothin, cefoxitin, cefotaxim, imipenem, gentamycin, amicacin, erythromycin, ciprofloxacin, metronidazole, clarithromycin, azithromycin and combinations thereof (e.g., clarithromycin + metronidazole or amoxicillin + clarithromycin).
- the compounds according to this invention may be administered in combination therapy separately, sequentially, simultaneously or chronologically staggered (such as e.g. as combined unit dosage forms, as separate unit dosage forms, as adjacent discrete unit dosage forms, as fixed or non-fixed combinations, as kit-of-parts or as admixtures) with one or more standard therapeutics as those mentioned above.
- combination may be present as a fixed combination, a non-fixed combination or a kit-of-parts.
- a “fixed combination” is defined as a combination wherein a first active ingredient and a second active ingredient are present together in one unit dosage or in a single entity.
- a “fixed combination” is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in admixture of simultaneous administration, such as in a formulation.
- Another example of a "fixed combination” is a pharmaceutical composition wherein the said first active ingredient and the said second active ingredient are present in one unit without being in admixture.
- kits-of-parts is defined as a combination wherein the said first active ingredient and the said second active ingredient are present in more than one unit.
- a “kit-of-parts” is a combination - - the said first active ingredient and the said second active ingredient are present separately.
- the components of the kit-of-parts may be administered separately, sequentially, simultaneously or chronologically staggered.
- Pantoprazole or examples 1 or 2 (10 ⁇ M each) were incubated with liver microsomes (source: all from GenTest except Mini Pig from TEBU ),incubation in 1 mg/ml protein, 100 mM Tris-HCI, pH 7.4, 1 mM NADPH 2 ). Reaction was terminated after 90 minutes by liquid nitrogen, the parent compound was detected by HPLC (10 mM KH 2 PO 4 , pH 7.4, acetonitril gradient 20-44 %).
- CYP cytochrome P450
- CYP2C19 and CYP3A4 were found to contribute to the oxidative metabolism of pantoprazole and its deuterated analogues. All other cytochrome P450 isoenzymes (CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A5) did not contribute to the metabolism of any of the compounds investigated above the lower limit of assay resolution.
- pantoprazole M2 (5-(difluorornethoxy)-2-IT(3-nriethoxy-4-sulfate-2-pyridvO- methyllsulfinvIl-IH-benzimidazole)
- M2 (difluoromethoxy)-2-[[(3-methoxy-4-sulfate-2-pyridyl)-methyl]sulfinyl]-1 H-benzimidazole) was determined.
- M2 involves the oxidation of the 4-methoxy-pyridyl group by CYP2C19 and subsequent conjugation with 3'-phosphoadenosine-5'-phosphosulfate (PAPS) by an unidentified sulphotransferase
- PAPS 3'-phosphoadenosine-5'-phosphosulfate
- the M2 formation rate was determined at nine different compound concentrations (0, 0.5, 1.0, 2.5, 5.0, 10.0, 25.0, 50.0 and 100 ⁇ Mol/L) incubated in duplicate for 60 min at 37° C. M2 was quantified using LC-MS/MS. M2 isolated from human urine was used as an external standard. The concentration to reach the half-maximal formation rate (K M -value) and the maximal formation rate (V max ) were obtained by non-linear regression analysis using the Michaelis- Menten equation. The intrinsic clearance (Cl ⁇ nt ) was obtained dividing V max over K M .
- Intrinsic clearance (Cl ⁇ nt )) in pooled human hepatocytes obtained upon incubation with pantoprazole and compounds according to the invention.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06777980A EP1912947A1 (fr) | 2005-07-26 | 2006-07-26 | Pantoprazole substitue d'un point de vue isotopique |
CN2006800344239A CN101268050B (zh) | 2005-07-26 | 2006-07-26 | 同位素取代的泮托拉唑 |
JP2008523355A JP5289951B2 (ja) | 2005-07-26 | 2006-07-26 | 同位体置換されたパントプラゾール |
CA2615678A CA2615678C (fr) | 2005-07-26 | 2006-07-26 | Pantoprazole substitue d'un point de vue isotopique |
AU2006274037A AU2006274037B2 (en) | 2005-07-26 | 2006-07-26 | Isotopically substituted pantoprazole |
US12/000,376 US7601737B2 (en) | 2005-07-26 | 2007-12-12 | Isotopically substituted proton pump inhibitors |
US12/458,704 US20100022779A1 (en) | 2005-07-26 | 2009-07-21 | Isotopically substituted proton pump inhibitors |
US12/461,985 US20100010047A1 (en) | 2005-07-26 | 2009-08-31 | Isotopically substituted proton pump inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05106874 | 2005-07-26 | ||
EP05106874.0 | 2005-07-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/064666 Continuation WO2007012650A1 (fr) | 2005-07-26 | 2006-07-26 | Inhibiteurs de pompe a protons isotopiquement substitues |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/000,376 Continuation US7601737B2 (en) | 2005-07-26 | 2007-12-12 | Isotopically substituted proton pump inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007012651A1 true WO2007012651A1 (fr) | 2007-02-01 |
Family
ID=35708921
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/064669 WO2007012651A1 (fr) | 2005-07-26 | 2006-07-26 | Pantoprazole substitue d'un point de vue isotopique |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1912947A1 (fr) |
JP (1) | JP5289951B2 (fr) |
CN (1) | CN101268050B (fr) |
AR (1) | AR054583A1 (fr) |
AU (1) | AU2006274037B2 (fr) |
CA (1) | CA2615678C (fr) |
TW (1) | TWI410409B (fr) |
WO (1) | WO2007012651A1 (fr) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009511481A (ja) * | 2005-10-06 | 2009-03-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 増強された治療特性を持つ、胃H+,K+−ATPaseの重水素化阻害剤 |
JP2010507576A (ja) * | 2006-10-23 | 2010-03-11 | コンサート ファーマシューティカルズ インコーポレイテッド | オキサゾリジノン誘導体および使用方法 |
JP2010520291A (ja) * | 2007-03-07 | 2010-06-10 | コンサート ファーマシューティカルズ インコーポレイテッド | 抗狭心症化合物としての重水素化ピペラジン誘導体 |
JP2010529994A (ja) * | 2007-06-13 | 2010-09-02 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換ピペラジン |
JP2011510079A (ja) * | 2008-01-22 | 2011-03-31 | コンサート ファーマシューティカルズ インコーポレイテッド | ゲフィチニブ誘導体 |
JP2018115199A (ja) * | 2007-05-01 | 2018-07-26 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
GB2560750A (en) * | 2017-03-24 | 2018-09-26 | Taher Darreh Shori | Biological methods |
US11473123B2 (en) | 2007-05-01 | 2022-10-18 | Concert Pharmaceuticals, Inc. | Morphinan compounds |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ565078A (en) * | 2005-07-26 | 2010-03-26 | Nycomed Gmbh | Deuterated proton pump inhibitors such as omeprazole |
JP5770997B2 (ja) * | 2009-12-09 | 2015-08-26 | 大塚製薬株式会社 | Cyp3a4の代謝機能測定方法 |
CN103349655B (zh) * | 2013-07-22 | 2015-04-29 | 南通广泰生化制品有限公司 | 枸橼酸他莫昔芬肠溶胶囊 |
JP2017527614A (ja) * | 2014-09-02 | 2017-09-21 | ブピンダー シン | 重水素化又は非重水素化分子及び医薬製剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005129A1 (fr) * | 1978-04-14 | 1979-10-31 | Aktiebolaget Hässle | Pyridylsulfinylbenzimidazoles substitués, compositions pharmaceutiques les renfermant et les intermédiaires pour leur préparation |
US6818200B2 (en) * | 1994-03-25 | 2004-11-16 | Isotechnika Inc. | Method of using deuterated calcium channel blockers |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA854287B (en) * | 1984-06-16 | 1986-02-26 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridines,process for their preparation,their use and medicaments containing them |
AU707748B2 (en) * | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
US6884429B2 (en) * | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
NO309305B1 (no) * | 1999-02-19 | 2001-01-15 | Norsk Hydro As | Anvendelse av benzaldehydderivater ved fremstilling av farmasöytiske preparater for forebygging og/eller behandling av kreft, samt visse nye benzaldehydderivater |
DE10123129A1 (de) * | 2001-05-02 | 2002-11-14 | Berolina Drug Dev Ab Svedala | Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel |
DE10162121A1 (de) * | 2001-12-12 | 2003-06-18 | Berolina Drug Dev Ab Svedala | Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel |
NZ565078A (en) * | 2005-07-26 | 2010-03-26 | Nycomed Gmbh | Deuterated proton pump inhibitors such as omeprazole |
-
2006
- 2006-07-26 AU AU2006274037A patent/AU2006274037B2/en not_active Ceased
- 2006-07-26 JP JP2008523355A patent/JP5289951B2/ja not_active Expired - Fee Related
- 2006-07-26 EP EP06777980A patent/EP1912947A1/fr not_active Withdrawn
- 2006-07-26 AR ARP060103223A patent/AR054583A1/es unknown
- 2006-07-26 WO PCT/EP2006/064669 patent/WO2007012651A1/fr active Application Filing
- 2006-07-26 CN CN2006800344239A patent/CN101268050B/zh not_active Expired - Fee Related
- 2006-07-26 TW TW095127342A patent/TWI410409B/zh not_active IP Right Cessation
- 2006-07-26 CA CA2615678A patent/CA2615678C/fr not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0005129A1 (fr) * | 1978-04-14 | 1979-10-31 | Aktiebolaget Hässle | Pyridylsulfinylbenzimidazoles substitués, compositions pharmaceutiques les renfermant et les intermédiaires pour leur préparation |
US6818200B2 (en) * | 1994-03-25 | 2004-11-16 | Isotechnika Inc. | Method of using deuterated calcium channel blockers |
Non-Patent Citations (1)
Title |
---|
ARNE BRÄNDSTRÖM ET AL: "Chemical reactions of omeprazole and omeprazole analogues VI. The reactions of omeprazole in the absence of 2-mercaptoethanol", ACTA CHEMICA SCANDINAVICA, no. 43, 1989, pages 595 - 611, XP009061378 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009511481A (ja) * | 2005-10-06 | 2009-03-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 増強された治療特性を持つ、胃H+,K+−ATPaseの重水素化阻害剤 |
US7598273B2 (en) | 2005-10-06 | 2009-10-06 | Auspex Pharmaceuticals, Inc | Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties |
JP2010507576A (ja) * | 2006-10-23 | 2010-03-11 | コンサート ファーマシューティカルズ インコーポレイテッド | オキサゾリジノン誘導体および使用方法 |
JP2010520291A (ja) * | 2007-03-07 | 2010-06-10 | コンサート ファーマシューティカルズ インコーポレイテッド | 抗狭心症化合物としての重水素化ピペラジン誘導体 |
JP2018115199A (ja) * | 2007-05-01 | 2018-07-26 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
JP2020073522A (ja) * | 2007-05-01 | 2020-05-14 | コンサート ファーマシューティカルズ インコーポレイテッド | モルフィナン化合物 |
US11473123B2 (en) | 2007-05-01 | 2022-10-18 | Concert Pharmaceuticals, Inc. | Morphinan compounds |
JP2010529994A (ja) * | 2007-06-13 | 2010-09-02 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換ピペラジン |
JP2011510079A (ja) * | 2008-01-22 | 2011-03-31 | コンサート ファーマシューティカルズ インコーポレイテッド | ゲフィチニブ誘導体 |
GB2560750A (en) * | 2017-03-24 | 2018-09-26 | Taher Darreh Shori | Biological methods |
WO2018172557A1 (fr) * | 2017-03-24 | 2018-09-27 | Darreh Shori Taher | Méthodes biologiques |
Also Published As
Publication number | Publication date |
---|---|
CN101268050B (zh) | 2012-11-28 |
JP2009502872A (ja) | 2009-01-29 |
AR054583A1 (es) | 2007-06-27 |
AU2006274037A1 (en) | 2007-02-01 |
AU2006274037B2 (en) | 2012-04-26 |
TW200745039A (en) | 2007-12-16 |
CA2615678A1 (fr) | 2007-02-01 |
CN101268050A (zh) | 2008-09-17 |
JP5289951B2 (ja) | 2013-09-11 |
CA2615678C (fr) | 2015-01-20 |
EP1912947A1 (fr) | 2008-04-23 |
TWI410409B (zh) | 2013-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2615678C (fr) | Pantoprazole substitue d'un point de vue isotopique | |
EP0654471B1 (fr) | Dérivés de pyridine, compositions pharmaceutiques les contenant, leur utilisation pour le préparation de médicaments de valeur thérapeutique ou préventive et procédé pour leur préparation | |
JPH0572391B2 (fr) | ||
IE58363B1 (en) | Pyridine derivatives and their production | |
JP2006516261A (ja) | 光学的に純粋な有効化合物の製造方法 | |
CA2615670C (fr) | Inhibiteurs de pompe a protons isotopiquement substitues | |
US7301030B2 (en) | Process for preparing (S)-pantoprazole | |
JPH05117268A (ja) | ピリジン化合物 | |
US7601737B2 (en) | Isotopically substituted proton pump inhibitors | |
JP2718945B2 (ja) | ピリジン誘導体及びそれを含有する潰瘍治療剤 | |
JPH08512037A (ja) | 置換されたアリールチオアルキルチオピリジン | |
US20080234326A1 (en) | Novel Salts of Pantoprazole and (S) - Pantoprazole | |
US20070219236A1 (en) | Dialkoxy-Imidazopyridines Derivatives | |
JP2008502654A (ja) | プロトンポンプインヒビターとしてのアミノ−ハロゲン−イミダゾピリジン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2615678 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008523355 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006777980 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 293/MUMNP/2008 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006274037 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2006274037 Country of ref document: AU Date of ref document: 20060726 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006274037 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680034423.9 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2006777980 Country of ref document: EP |